Medication-info.com Search Menu

Gadoterate Meglumine: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning Being discontinued since June 30, 2026
Strength:
376.9 mg/mL
Active ingredient:

Patient information: uses, side effects, how to take - Gadoterate Meglumine

What is the most important information I should know about Gadoterate Meglumine Injection?

  • GBCAs like Gadoterate Meglumine Injection may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if Gadoterate Meglumine Injection is safe and effective with intrathecal use. Gadoterate Meglumine Injection is not approved for this use.
  • Gadoterate Meglumine Injection contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).
  • It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.
  • Rarely patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.
  • There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist or MultiHance. Gadolinium stays in the body the least after Gadoterate Meglumine Injection, Gadavist or ProHance.
  • People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.
  • Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Gadoterate Meglumine Injection.

What is Gadoterate Meglumine Injection?

  • Gadoterate Meglumine Injection is a prescription medicine called a gadolinium-based contrast agent (GBCA). Gadoterate Meglumine Injection, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner.
  • An MRI exam with a GBCA, including Gadoterate Meglumine Injection, helps your doctor to see problems better than an MRI exam without a GBCA.
  • Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.

Do not receive Gadoterate Meglumine Injection if you have had a severe allergic reaction to Gadoterate Meglumine Injection.

Before receiving Gadoterate Meglumine Injection, tell your healthcare provider about all your medical conditions, including if you:

  • have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.
  • are pregnant or plan to become pregnant. It is not known if Gadoterate Meglumine Injection can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as Gadoterate Meglumine Injection is received during pregnancy.

  • have kidney problems, diabetes, or high blood pressure.
  • have had an allergic reaction to dyes (contrast agents) including GBCAs.

What are possible side effects of Gadoterate Meglumine Injection?

  • See "What is the most important information I should know about Gadoterate Meglumine Injection?"
  • Allergic reactions. Gadoterate Meglumine Injection can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.

The most common side effects of Gadoterate Meglumine Injection include: nausea, headache, pain, or cold feeling at the injection site, and rash.

These are not all the possible side effects of Gadoterate Meglumine Injection.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective uses of Gadoterate Meglumine Injection.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about Gadoterate Meglumine Injection that is written for health professionals.

What are the ingredients in Gadoterate Meglumine Injection?

Active ingredient: gadoterate meglumine

Inactive ingredients: DOTA, water for injection

Manufactured for: Fresenius Kabi USA, LLC

For more information, call 1-800-551-7176.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

451747E 24UG06 Rev. 05/2025

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: ANDA 215304 · View the label on DailyMed

Revision date stated in the text: May 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Gadoterate Meglumine

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Drug class Gadolinium-based Contrast Agent
Active ingredient Gadoterate meglumine 376.9 mg/mL
Dosage form Injection
Route Intravenous
Marketing status listed in the FDA NDC Directory
Company (applicant) HENGRUI PHARMA
FDA approval ANDA 215304Abbreviated New Drug Application (ANDA) – generic drug Approved April 11, 2022
Manufacturers 3 labelers list this drug on DailyMed
Drug shortage
  • Being discontinued since June 30, 2026
Packages (NDC)
Package
376.9 mg/mL – 5 ml in 1 vial / 1 in 1 carton / 10 in 1 box NDC 65219-080-01
376.9 mg/mL – 10 ml in 1 vial / 1 in 1 carton / 10 in 1 box NDC 65219-082-01
376.9 mg/mL – 15 ml in 1 vial / 1 in 1 carton / 10 in 1 box NDC 65219-084-01
376.9 mg/mL – 20 ml in 1 vial / 1 in 1 carton / 10 in 1 box NDC 65219-086-01

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.